FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to resuscitation and intensive care, and can be used in respiratory therapy in new coronavirus infection COVID-19 in patients with respiratory failure, who are on spontaneous breathing. That is ensured by inhalations with nitrogen oxide in high doses of 160–200 ppm for 20–30 minutes twice a day. In addition, continuous inhalation of nitrogen oxide in dose of 20 ppm is carried out in intervals between inhalations of nitrogen oxide in high doses. Inhalations are carried out until symptoms of the disease disappear.
EFFECT: method provides prolonged improvement of gas exchange, prevention of development of cardiac complications, higher respiratory comfort, as well as reducing the duration of the disease by activating the sanogenesis mechanisms of the respiratory tract and potentiating the adjuvant antiviral effect in the patients with respiratory failure spontaneously breathing in COVID-19.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| Respiratory therapy method for new coronavirus infection COVID-19 in patients on artificial lung ventilation | 2020 |
|
RU2744550C1 |
| METHOD OF TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19 WITH SPONTANEOUS RESPIRATION | 2023 |
|
RU2824264C1 |
| METHOD FOR TREATING PATIENTS WITH A NEW CORONAVIRUS INFECTION COVID-19 WITH HIGH-FLOW OXYGENATION | 2022 |
|
RU2787175C1 |
| METHOD FOR IMPROVING OXYGENATING PULMONARY FUNCTION IN THE PATIENTS WITH A NEW CORONAVIRAL INFECTION (COVID-19) WITH RESPIRATORY FAILURE WHO ARE ON RESPIRATORY SUPPORT | 2020 |
|
RU2735797C1 |
| METHOD FOR PREVENTION OF NOSOCOMIAL PNEUMONIA IN CARDIOSURGICAL PATIENTS | 2023 |
|
RU2817677C1 |
| METHOD FOR TREATING PATIENTS WITH HIV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASES WITH MODERATE AND SEVERE COVID-19 | 2022 |
|
RU2793414C1 |
| METHOD FOR PREOPERATIVE PREPARATION OF PATIENTS WITH LUNG CANCER AFTER SUFFERING COVID-19 ASSOCIATED PNEUMONIA | 2021 |
|
RU2766291C1 |
| METHOD FOR DETERMINING THE FUNCTIONAL ACTIVITY OF THE HUMAN COMPLEMENT SYSTEM FOR PREDICTING THE SEVERITY OF THE COURSE OF A SYSTEMIC INFLAMMATORY REACTION | 2021 |
|
RU2756764C1 |
| AGENT FOR REDUCING RISK AND RELIEVING SYMPTOMS OF BETA-CORONAVIRUS INFECTION | 2021 |
|
RU2747890C1 |
| A METHOD FOR THE TREATMENT OF RESPIRATORY FAILURE (HYPOXEMIA) IN PATIENTS WHO HAVE HAD AN INFECTION WITH THE SARS-CoV-2 VIRUS | 2022 |
|
RU2784998C1 |
